Premier Biomedical Updates “Stock Day” Listeners on 2017 Accomplishments; Sketches Outline Towards $5 Billion CBD Oil Market Penetration


Premier Biomedical Updates “Stock Day” Listeners on 2017 Accomplishments; Sketches Outline Towards $5 Billion CBD Oil Market Penetration
Jan 17, 2018
OTC Disclosure & News Service

PHOENIX, Jan. 17, 2018 (GLOBE NEWSWIRE) — The Uptick Newswire “Stock Day” podcast keeps investors up to date on the latest penny stock news by bringing transparency in the micro-cap side of the market. Connect with “Stock Day” and to over 600+ CEO interviews on the OTC, Pink Sheets and micro-cap news from around the world by following Stock Day’s YouTube, Google Play and iTunes. Everett Jolly, CEO and host of “Stock Day”, had received many emails and calls to have as a return guest, William A. Hartman, CEO of Premier Biomedical Inc. (OTC:BIEI) (“Company”), which is rapidly growing in the hemp oil pain relief industry.

Starting off the interview, Mr. Hartman discussed the positive achievements that Premier Biomedical attained throughout 2017. Premier Biomedical had promising results with their R&D Cancer Research efforts, outperforming the leading anti-cancer drug currently on the market in animal testing. Lacking the funding required to complete the development of this anti-cancer drug, Premier Biomedical had to put this uniquely promising research on hold in order to develop a revenue-producing technology product which would provide a steady cash flow. Even though the funding for the cancer R&D has slowed, the Company has not stopped research & development, with the most recent filing of a patent application in this potentially lucrative area of the medical market. Mr. Hartman briefly touched on the recently filed patent application involving the use of a laser procedure to destroy disease antigens which would be a very promising development for medical science in the future.

Industry analysts predict that the medically promising hemp oil topical pain product industry could grow into an estimated $5 Billion market by 2025, prompting Premier Biomedical’s leap into the hemp oil pain relief product arena. With the successful launch of their first product, a topical pain patch, in the first quarter of 2017, Premier Biomedical had to search long and hard for a manufacturing source that was able to keep up with the Company’s production volume. Throughout 2017, Premier Biomedical launched a total of five new hemp oil topical pain relief products including a 50 mg, 96-hour pain patch, a hemp oil based roll-on, a water based roll-on, a hemp oil spray and a 2 ounce jar ointment.

To gain access to the Sports Injury Industry, the Company added Carl Eller to Premier Biomedical’s team. Carl Eller is the President of the NFL Retired Players Association. The Chief Medical Officer/Chief Technical Officer for Premier Biomedical is also the Chief Medical Officer of the NFL Retired Players Association. This gives Premier Biomedical the network to help fight the opioid pain killer addiction within the sports industries.

Mr. Hartman elaborated on the recent partnership with (OTC:HEWA), the largest retail mail-order pharmacy in the U.S., which is based in the Cincinnati metropolitan area.

The Company was recently featured on a “New to the Street” segment, which is part of the Fox Business Network (FBN), reaching over 90 million homes. Mr. Hartman will appear in five additional segments over the coming months.

Mr. Hartman emphasized that all of Premier Biomedical’s pain relief products are derived from 100% legal industrial HEMP and do not contain measurable quantities of the psychoactive element THC. Premier Biomedical would like the public to become aware of the effectiveness of their CBD topical pain products in reducing pain as an alternative to opioid pain medications. This push coincides with President Donald Trump declaring the opioid crisis as a public health emergency.

To listen to the interview in its entirety, please click here:

About Uptick Newswire and the “Stock Day Podcast”
Uptick Newswire is a private company reaching out to the masses keeping investors and shareholders up to date on company news and bringing transparency to the undervalued, undersold, micro-cap stocks of the market and is the sole producer of the Uptick Network “Stock Day” Podcast. The Uptick Network “Stock Day” Podcast is an extension of Uptick Newswire and has recently launched the Video Interview Studio located in Phoenix, Arizona with its new host Kathryn Donnelly.
Follow us and keep an eye on Uptick’s YouTube, Twitter, and Facebook for additional radio and video shows produced by Uptick!

Marijuana Co. of America Stock Quote Updates Available at

Uptick Newswire is proud to report on Marijuana companies including but not limited to Northsight Capital and Player’s Network, Inc.

Investors Hangout is a proud sponsor of “Stock Day”. Uptick encourages listeners to visit Premier Biomedical’s message board on:

About Premier Biomedical Inc.
Premier Biomedical, Inc. (OTC:BIEI) is a research-based publicly traded company that intends to discover and develop medical treatments for a wide range of diseases in humans. Premier has obtained, via exclusive license agreements, the technology behind three granted US Patents, multiple pending provisional patents, and a PCT Europe National Patent. Founded in 2010, Premier has partnered with the University of Texas at El Paso (UTEP). The company’s R&D efforts are centered in El Paso, TX, and their business offices are in Western Pennsylvania. The Company is a fully-reporting issuer whose common stock trades on the OTC marketplace maintained by OTC Markets Group, Inc. under the ticker symbol “BIEI.” For more information please visit our website:

This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties.

The statements in this press release have not been evaluated by the Food and Drug Administration (FDA) and are not intended to diagnose, treat or cure any disease. The Company does not sell or distribute any products that are in violation of the United States Controlled Substances Act. The Company does sell and distribute hemp-based products.

Uptick Newswire LLC
Everett Jolly, CEO/Founder
10000 N. 31st Avenue C307
Phoenix, AZ 85051

Source: Uptick Newswire

Primary Logo

Copyright © 2018 GlobeNewswire. All Rights Reserved

The above news release has been provided by the above company via the OTC Disclosure and News Service. Issuers of news releases and not OTC Markets Group Inc. are solely responsible for the accuracy of such news releases.